Merck & Co. Inc. (MRK) is in the Pharma Industry

• Sort by
• View by Content Type

• Schering-Plough Now in the Feds' Crosshairs

  Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...

  Discussion threads 2008-07-10

  Tags: ENHANCE Trial, Schering, Schering-Plough Corp., trial result, Vytorin, Zocor, Merck & Co. Inc.

• Is Merck Hanging Schering Out to Dry on Vytorin?

  Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...

  Discussion threads 2008-07-07

  Tags: ENHANCE Trial, Merck & Co. Inc., Schering, Vytorin, Zocor

• Cheaper Zocor throws generic market a curveball

  A recent change in policy adopted by large pharmaceutical firm Merck to offer greater discounts for its cholesterol-lowering drug Zocor has given employer-clients, pharmacy benefit managers and insurers a tough benefit design decision: Should they stick w A recent change in policy adopted by large pharmaceutical firm Merck to offer...

  Research articles 2006-10-01

  Tags: generic, insurance company, Merck & Co. Inc., PBM, Zocor

• Cheaper Zocor throws generic market a curveball

  A recent policy change by Merck to offer greater discounts for its cholesterol-lowering drug Zocor has employers, pharmacy benefit managers and insurers faced with making a tough decision: Should they follow what has been general tradition to this point a A recent policy change by Merck to offer greater discounts...

  Research articles 2006-09-15

  Tags: insurance company, Merck & Co. Inc., PBM, Zocor

• Zocor move muddles generics strategies.(usage of generic drugs)

  Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck & Co.'s decision to offer pricing incentives to encourage insurers and pharmacy benefit managers to favor its brand-name drug Zocor over recently introduced generic versions has initiat Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck &...

  Research articles 2006-07-10

  Tags: generic, Merck & Co. Inc., pricing strategy, strategy, Zocor

• Ranbaxy gets taste of Merck bestseller.

  May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva Pharmaceutical are likely to get a windfall by having six months without competition to sell their generic versions of Merck's blockbuster cholesterol drug Zocor. May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva...

  Research articles 2006-05-03

  Tags: Merck & Co. Inc., Ranbaxy, ZOCOR

• Merck & Co. Inc. (Active Pharmaceutical Ingredient Watch).(to change label for Zocor)(Brief Article)

  MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor ... MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor simvastatin to recommend a 40mg starting dose...

  Research articles 2003-04-28

  Tags: Merck & Co. Inc., Zocor

• Merck & Co. Inc. (Active Pharmaceutical Ingredient Watch).(alters Zocor label)(Brief Article)

  MERCK & Co. Inc. reports that changes to the existing label for cholesterol-lowering drug Zocor simvastatin further clarify the risk of myopathy and rhabdomyolysis, particularly with higher doses and when used with certain drugs. Merck reques MERCK & Co. Inc. reports that changes to...

  Research articles 2002-06-17

  Tags: Merck & Co. Inc., Zocor

• MERCK & CO. Inc.'s.

  MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval ... MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval as the first cholesterol-modifying drug indicated to increase HDL cholesterol, or good cholesterol.

  Research articles 1999-08-23

  Tags: Merck & Co. Inc., Zocor

• Merck Seeks Approval to Sell Higher Dosage of Cholesterol Fighter.(Originated from The Star-Ledger, Newark, N.J.)

  Apr. 24--Moving to fend off new competition, Merck & Co. plans to seek approval later this year to sell a higher dosage of its best-selling cholesterol fighter, Zocor. Apr. 24--Moving to fend off new competition, Merck & Co. plans to seek...

  Research articles 1997-04-24

  Tags: Merck & Co. Inc., Zocor

• New Products Boost New Jersey-Based Merck's Earnings.(Originated from The Star-Ledger, Newark, N.J.)

  Apr. 17--Merck & Co., the nation's biggest drug maker, yesterday reported that first-quarter earnings rose 18 percent on the strength of several new medications, particularly its cholesterol fighter, Zocor. Apr. 17--Merck & Co., the nation's biggest drug maker, yesterday reported...

  Research articles 1997-04-17

  Tags: Merck & Co. Inc., Zocor

• Cholesterol-lowering treatment with Merck's Zocor shown to save lives, prevent heart attacks in elderly

  the landmark Scandinavian Simvastatin Survival Study (4S) demonstrate that treating elderly patients who have heart disease and high cholesterol with ZocorR simvastatin reduced death due to heart disease by 43 percent and reduced death from any cause by 34 percent.

  Research articles 1995-11-15

  Tags: Merck & Co. Inc., ZOCOR

Additional Resources

• Research and Markets: The Merck & Co. Company Profile Analyzes the Critical Components That Make up This Pharmaceutical Company

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/862fdd/merck_co_ims_com) has announced the addition of the "Merck & Co IMS Company Profile" company profile to their offering. These Company Profiles give you the authoritative insight into a company at a strategic and local level. Each individual profile analyzes the...

  Articles 2008-11-05

• New, more efficient anti-AIDS drug for untreated patients

  WASHINGTON AFP — Medical researchers on Sunday unveiled clinical trials of new anti-AIDS drug that better controls the spread of the deadly virus among previously untreated patients. Developed by US pharmaceutical giant Merck and Co, Isentress is the first of a new type of anti-AIDS medication called HIV...

  Articles 2008-10-26

• Odyssey Thera Announces New Equity Financing

  New Funds to Help Guide the Next Stage of Company's Development SAN RAMON, Calif., Oct. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced today a new equity financing, with Merck and Co., Inc. as one of the investors. Existing investors Burrill & Company, HBM Partners, and Healthcap also...

  Articles 2008-10-07

• CDC recommends shingles vaccine for all older adults

  "Immunizations are not just for babies. They are important for health across the lifespan." This was the message from Donna Weaver, RN, of The Centers for Disease Control and Prevention CDC at the 2008 Center for American Nurses CAN LEAD Conference in Washington, D.C. in June. The CDC...

  Articles 2008-08-01

• Research and Markets: In-depth Insight into the Partnering Interests and Activities of Merck & Co

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/b52ba1/merck_co_partner) has announced the addition of the "Merck & Co Partnering Guide 2008" company profile to their offering. The Merck & Co Partnering Guide 2008 provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma...

  Articles 2008-07-29

• BellwetherReport.com Free Analyst Review for ACTU, ANST, SGP and MRK

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased research on the companiesmentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of the...

  Articles 2008-03-31

• Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations.

  LOS ANGELES, September 10 /PRNewswire/ -- - The once-daily HIV treatment would greatly increase effectiveness for patients, but Gilead Sciences and Merck and Co. have failed to register it in countries where it is needed most AIDS Healthcare...

  Articles 2007-09-10

• Scholars program

  The Merck Co. Foundation and Princeton University are creating a global health scholars program and lecture series. The program will provide Princeton students with funding to pursue global-related internships...

  Articles 2007-06-25